Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AD/PD 2022

Latest videos from AD/PD 2022

View all
2:38
Deep-learning tool can screen electronic health records to identify undiagnosed cognitive impairment
Sudeshna Das • 16 Mar 2022
6:26
NICARA for automated morphometry and connectomic analysis
Markus Butz-Ostendorf • 14 Mar 2022
4:56
Single center pilot study of TPS in Alzheimer’s disease
Lars Wojtecki • 17 Mar 2022
1:14
The potential of vaccination for neurodegenerative disease
Johanne Kaplan • 17 Mar 2022

Biology

View all
2:37
Lowering synaptogyrin-3 expression rescues tau-induced memory defects and synaptic loss
Pablo Largo-Barrientos • 16 Mar 2022
3:28
Reframing the way we think about Alzheimer’s disease
Giovanni Frisoni • 11 Mar 2022
4:19
Alzheimer’s risk genes and their effect on synapses
Thomas Südhof • 17 Mar 2022
3:25
Role of TAM receptors in Alzheimer’s disease
Greg Lemke • 18 Mar 2022

Biomarkers

View all
1:50
Advances in Alzheimer’s disease biomarkers & therapies
Stephen Pasternak • 16 Mar 2022
1:50
Strengthening diversity in dementia biomarkers research
Pamela Lukasewicz Ferreira • 16 Mar 2022
1:28
Impact of blood-based biomarkers on Alzheimer’s disease treatments
Charlotte Teunissen • 17 Mar 2022
1:02
Differences between Alzheimer’s disease biomarkers: p-Tau181, p-Tau231 & p-Tau217
Nicholas Ashton • 18 Mar 2022

Trial Updates

View all
2:00
Safety and PK data from the Phase I trial of COR588
Michael Detke • 23 Mar 2022
19:01
GAIN trial: evidence of target engagement and activity with atuzaginstat in Alzheimer’s disease
Michael Detke • 23 Mar 2022
6:13
PERISCOPE-ALZ trial of zagotenemab
Adam Fleisher • 22 Mar 2022
6:01
The development of lecanemab & rationale behind its unique binding profile
Lars Lannfelt • 17 Mar 2022
The content of VJDementia is intended for healthcare professionals